Research and Markets: China Valsartan Hydrochlorothiazide Market to 2018

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/6kgr9m/investigation) has announced the addition of the "Investigation Report on China's Valsartan Hydrochlorothiazide Market, 2009-2018" report to their offering.

According to WHO, one-third of the world's adults have hypertension. The global market value of antihypertensive drugs is tens of billion dollars.

Due to the long history of antihypertensive drugs, most hypertensive patients need 2 or more kinds of antihypertensive drugs to reduce the blood pressure to a normal level. There are more than 20 compound preparations of sartan drugs in global market.

The first category is the compound preparation of sartan and diuretic hydrochlorothiazide. Because the compound of sartan drugs and diuretic has better effect than other medication compounds, most sartan and hydrochlorothiazide compound preparations are approved by FDA, including the compound preparation of diuretic chlorthalidone and azilsartan.

The second category is the compound preparation of sartan and calcium antagonist. The third category is the direct renin inhibitor and sartan compound preparation. The fourth one is triplex compound preparation. Novartis developed valsartan compound preparation after valsartan was launched. In October 1997, the compound preparation of valsartan hydrochlorothiazide was successfully developed by Novartis and approved by FDA with the trade name ""CoDiovan"". Unlike valsartan, valsartan hydrochlorothiazide tablet can only treat hypertension instead of congestive heart failure and myocardial infarction.

Key Topics Covered:

1 Relevant Concepts of Valsartan Hydrochlorothiazide

2 Market Overview of Valsartan Hydrochlorothiazide in China, 2009-2013

3 Investigation on Sales Value of Valsartan Hydrochlorothiazide in China, 2009-2013

4 Investigation on Market Share of Major Valsartan Hydrochlorothiazide Manufacturers in China, 2009-2013

5 Investigation on Market Size of Valsartan Hydrochlorothiazide by Dosage Form in China, 2009-2013

6 Reference Price of Valsartan Hydrochlorothiazide Produced by Different Enterprises in China Hospital Market, 2014

7 Analysis on Major Valsartan Hydrochlorothiazide Manufacturers in China, 2009-2014

8 Market Overview of Valsartan Hydrochlorothiazide in China, 2014-2018

Companies Mentioned

  • Novartis
  • Jiangsu Wangao Pharmaceutical Co., Ltd.
  • China Resources Saike Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Cisen Pharmaceutical Co., Ltd.

For more information visit http://www.researchandmarkets.com/research/6kgr9m/investigation

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals